SCI时时刷

search
+
Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia
Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia
A tyrosine kinase inhibitor (TKI) such as Imatinib (IM) is the preferred treatment for Chronic Myeloid Leukemia (CML). How...
Radiation-induced exosomal miR-21 enhances tumor proliferation and invasiveness in breast cancer: implications for poor prognosis in radiotherapy patients
Radiation-induced exosomal miR-21 enhances tumor proliferation and invasiveness in breast cancer: implications for poor prognosis in radiotherapy patients
Radiotherapy is widely used as an effective non-surgical strategy to control malignant tumors. However, recurrence is one ...
Identification of a novel subtype of SPP1 + macrophages expressing SIRPα: implications for tumor immune evasion and treatment response prediction
Identification of a novel subtype of SPP1 + macrophages expressing SIRPα: implications for tumor immune evasion and treatment response prediction
SPP1 + macrophages are among the major phagocytic cells, yet promoting tumor immune evasion and predicting unf...
Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses
Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses
Tumor-associated macrophages (TAMs) are immunosuppressive cells within the tumor microenvironment (TME) that hinder anti-t...
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances
Immunotherapy has transformed the landscape of cancer treatment, with chimeric antigen receptor (CAR)-engineered T (CAR-T)...
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
Relapsed/refractory T cell-derived malignancies present with high heterogeneity and poor prognoses. Recently, chimeric ant...
CUL4A-DDB1-circRFWD2 E3 ligase complex mediates the ubiquitination of p27 to promote multiple myeloma proliferation
CUL4A-DDB1-circRFWD2 E3 ligase complex mediates the ubiquitination of p27 to promote multiple myeloma proliferation
Multiple myeloma (MM) is an incurable disease characterized by the abnormal expansion of plasma cells in the bone marrow (...
Malignant pleural effusion facilitates the establishment and maintenance of tumor organoid biobank with multiple patient-derived lung tumor cell sources
Malignant pleural effusion facilitates the establishment and maintenance of tumor organoid biobank with multiple patient-derived lung tumor cell sources
The Patient-Derived Organoids (PDOs) has demonstrated significant potential in personalized medicine. However, the initial...
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience
Urothelial carcinoma (UC) of the urinary bladder has significant challenges in treatment due to its diverse genetic landsc...
Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities
Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities
Despite therapeutic advancements, multiple myeloma (MM) remains incurable. NK cells have emerged as a promising option for...
High-throughput screening for optimizing adoptive T cell therapies
High-throughput screening for optimizing adoptive T cell therapies
Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, it...
Targeting SPP1-orchestrated neutrophil extracellular traps-dominant pre-metastatic niche reduced HCC lung metastasis
Targeting SPP1-orchestrated neutrophil extracellular traps-dominant pre-metastatic niche reduced HCC lung metastasis
The mechanisms by which tumor-derived factors remodel the microenvironment of target organs to facilitate cancer metastasi...
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
Chimeric antigen receptor (CAR) T-cell therapy represents a highly efficacious treatment modality demonstrated to enhance ...
Nuclear porcupine mediates XRCC6/Ku70 S-palmitoylation in the DNA damage response
Nuclear porcupine mediates XRCC6/Ku70 S-palmitoylation in the DNA damage response
The activation of the DNA damage response (DDR) heavily relies on post-translational modifications (PTMs) of proteins, whi...
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
The basic idea of modulating the immune system to better recognize and fight tumor cells has led to the successful introdu...
Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma
Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma
The phosphatidylinositol 3‑kinase/protein kinase B (PI3K/AKT) signaling pathway is critically active in many cell ty...
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance
Developing resistance to cancer treatments is a major challenge, often leading to disease recurrence and metastasis. Under...
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated promising clinical efficacy in B-cell malignancies,...
Spatial immunogenomic patterns associated with lymph node metastasis in lung adenocarcinoma
Spatial immunogenomic patterns associated with lymph node metastasis in lung adenocarcinoma
Lung adenocarcinoma (LUAD) with lymph node (LN) metastasis is linked to poor prognosis, yet the underlying mechanisms rema...
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications
In recent years, immunotherapy has developed rapidly as a new field of tumour therapy. However, the efficacy of tumour imm...
Optimizing CD8+ T cell-based immunotherapy via metabolic interventions: a comprehensive review of intrinsic and extrinsic modulators
Optimizing CD8+ T cell-based immunotherapy via metabolic interventions: a comprehensive review of intrinsic and extrinsic modulators
CD8+ T cells are integral to the effective management of cancer and infectious diseases due to their cytotoxic functions. ...
Natural killer cell-based cancer immunotherapy: from basics to clinical trials
Natural killer cell-based cancer immunotherapy: from basics to clinical trials
Cellular immunotherapy exploits the capacity of the human immune system in self-protection and surveillance to achieve the...
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma
Relapsed/refractory (R/R) primary and secondary central nervous system lymphomas (PCNSL, SCNSL) are associated with short ...
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies
Until recently, treatment options for patients diagnosed with Acute Myeloid Leukemia (AML) were limited and predominantly ...
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors
Blocking cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) shows substantial antitumor efficacy. Here, we report the pr...
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation
Aberrant activation of mesenchymal epithelial transition (MET) has been considered to mediate primary and acquired resista...
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment
Chimeric antigen receptor (CAR) T cell therapy, which targets tumors with high specificity through the recognition of part...
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response
Interactions between colorectal cancer (CRC) cells and the noncancerous cells in the tumor microenvironment (TME) induce m...
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers
Precision medicine has drastically changed cancer treatment strategies including KRAS-mutant cancers which have been undru...
Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia
Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia
Besides chemotherapy and hematopoietic stem cell transplantation (HSCT), autologous T cells can also serve as a new treatm...
阅读更多
format_indent_increase